reslizumab   Click here for help

GtoPdb Ligand ID: 8091

Synonyms: CDP-835 | CDP835 | Cinqaero® | Cinqair® | JES1-39D10 | SCH55700
Approved drug Immunopharmacology Ligand
reslizumab is an approved drug (EMA & FDA (2016))
Compound class: Antibody
Comment: Reslizumab is a monoclonal antibody with antiinflammatory action. It is designed to treat eosinophil-driven inflammatory conditions of the airways, skin and gastrointestinal tract [1,4].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: reslizumab

Classification Click here for help
Compound class Antibody
Approved drug? Yes. FDA (2016)  |  EMA (2016)
International Nonproprietary Names Click here for help
INN number INN
8106 reslizumab
Synonyms Click here for help
CDP-835 | CDP835 | Cinqaero® | Cinqair® | JES1-39D10 | SCH55700
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 279
Other databases
GtoPdb PubChem SID 249565771
Search PubMed clinical trials reslizumab
Search PubMed titles reslizumab
Search PubMed titles/abstracts reslizumab
Wikipedia Reslizumab